Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872557 | 0.84 | OPRK1 (0.45) | SMN1; SMN2NPC1RAB9AOPRK1MMP1 | |
| SCHEMBL5872584 | 0.84 | OPRK1 (0.45) | SMN1; SMN2NPC1RAB9AOPRK1MMP1 | |
| SCHEMBL5872558 | 0.84 | OPRK1 (0.45) | SMN1; SMN2NPC1RAB9AOPRK1MMP1 | |
| SCHEMBL7830999 | 0.83 | PTGDR2 (0.44) | SMN1; SMN2NPC1RAB9AOPRK1MMP1 | |
| SCHEMBL5872510 | 0.83 | PTGDR2 (0.44) | SMN1; SMN2NPC1RAB9AOPRK1MMP1 | |
| SCHEMBL5132634 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AMMP1MMP3 | |
| SCHEMBL5746454 | 0.81 | PTGDR2 (0.44) | SMN1; SMN2NPC1RAB9AMMP1MMP3 | |
| SCHEMBL11445686 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AOPRK1MMP1 | |
| SCHEMBL11464607 | 0.79 | GFER (0.44) | SMN1; SMN2NPC1RAB9AMMP1MMP3 | |
| SCHEMBL5872581 | 0.79 | GPR174 (0.46) | SMN1; SMN2NPC1RAB9AMMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098338-B2 | 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives | WYETH (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040116437-A1 | 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives | WYETH (US) | 2004-06-17 | — | — | US | disclosed |
| US-6706714-B2 | USEFUL FOR THE TREATMENT OF DISORDERS INVOLVING THE CENTRAL NERVOUS SYSTEM SUCH AS OBSESSIVE-COMPULSIVE DISORDER, DEPRESSION, ANXIETY, SCHIZOPHERNIA, MIGRAINE, SLEEP OR EATING DISORDER, OBESITY, TYPE II DIABETES AND EPILEPSY | WYETH CORP (US) | 2004-03-16 | — | — | US | disclosed |
| US-20030060468-A1 | 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives | WYETH (US) | 2003-03-27 | — | — | US | disclosed |
| US-6476032-B2 | 5HT2C RECEPTOR AGONISTS TO TREAT SCHIZOPHRENIA AND CENTRAL NERVOUS SYSTEM DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; ANTIDEPRESSANTS, MIGRAINE; SLEEP DISORDERS; EATING DISORDERS; OBESITY; ANTIDIABETIC, -EPILEPTIC AND ANXIOLYTIC AGENTS | WYETH | 2002-11-05 | — | — | US | disclosed |
| US-6372745-B1 | TREATMENT OF OBESITY IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-16 | — | — | US | disclosed |
| US-20010051622-A1 | 2,3,4,4a-tetrahydro-1H-pyrazino-[1,2a] quinoxalin-5- (6H) one derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1140940-A1 | 2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QINOXALIN-5(6H)ONE DERIVATES BEING 5HT2C AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035922-A1 | 2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QUINOXALIN-5(6H)ONE DERIVATES BEING 5HT2C AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060468-A1 | 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives | NPY2R, HCRTR2, HTR2C | SMN1; SMN2 3134/4885NPC1 1858/4885RAB9A 1289/4885 |
| US-20010051622-A1 | 2,3,4,4a-tetrahydro-1H-pyrazino-[1,2a] quinoxalin-5- (6H) one derivatives | HTR2C, HTR3C, NPY2R | SMN1; SMN2 3132/4885NPC1 1742/4885RAB9A 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.